Edwards Lifesciences Corporation — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. Although the request metadata refers to 2023 Q4, this is an annual 10-K; the supplied filing text does not provide a clear standalone fourth-quarter results summary. Amounts below are U.S. dollars.
Business context
Edwards develops and sells medical technologies focused on structural heart disease and critical care monitoring. Its product groups are transcatheter aortic valve replacement (TAVR), transcatheter mitral and tricuspid therapies (TMTT), surgical structural heart, and critical care. TAVR represented 65% of 2023 sales. The company announced plans to spin off Critical Care as a separate public company around the end of 2024.
Key financial metrics
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Net sales | $6,004.8 million | $5,382.4 million | +11.6% |
| Gross profit / gross margin | $4,625.0 million / 77.0% | $4,302.0 million / 79.9% | Margin down about 2.9 percentage points |
| Operating income / operating margin | $1,534.1 million / 25.5% | $1,748.5 million / 32.5% | Operating income down 12.3% |
| Net income attributable to Edwards | $1,402.4 million | $1,521.9 million | Down 7.9% |
| Diluted EPS | $2.30 | $2.44 | Down 5.7% |
| Cash from operations | $895.8 million | $1,218.2 million | Down $322.4 million |
| Capital expenditures | $253.0 million | $244.6 million | Up $8.4 million |
At year-end, cash and cash equivalents were $1,144.0 million, short-term investments $500.5 million, and current assets $4,035.7 million against current liabilities of $1,195.4 million. Long-term investments were $583.9 million. Debt consisted principally of $600.0 million of 4.3% senior notes due 2028 (carrying value $597.0 million); the $750.0 million revolving credit facility had no borrowings outstanding.
Sales by product group were TAVR $3,879.8 million (+10.3%), TMTT $197.6 million (+70.1%), surgical heart valve therapy $999.3 million (+11.9%), and Critical Care $928.1 million (+8.5%). Research and development expense was $1,071.8 million, approximately 17.8% of sales, up 13% year over year.
Material changes versus 2022
- Sales increased $622.4 million, driven mainly by TAVR growth. Japan sales declined 4.5%; U.S., Europe, and Rest of World sales grew.
- Despite higher sales, operating income and EPS declined. Gross margin pressure was attributed primarily to foreign-exchange movements; higher SG&A and R&D also weighed on results.
- Intellectual-property agreement and litigation expense rose to $203.5 million from $15.8 million. The Medtronic agreement included a $300.0 million upfront payment, annual royalties tied to sales of certain products, and a 15-year mutual covenant not to sue covering specified structural-heart patents.
- Cash from operations fell, primarily due to the $300.0 million Medtronic payment, partly offset by higher bonus payments in 2022. Inventory also increased to $1,168.2 million from $875.5 million.
- Edwards repurchased 11.4 million shares for an aggregate $880.5 million during 2023 and ended the year with $1.0 billion of remaining repurchase authorization. The company has no current plan to pay cash dividends.
Outlook, risks, contingencies, and unusual items
- Management expected approximately $300 million of capital expenditures in 2024. The filing text does not provide clear numerical 2024 sales or EPS guidance.
- The planned Critical Care spin-off was expected around year-end 2024, subject to customary conditions, including board approval, regulatory filings, and tax-related conditions. Timing, tax-free treatment, costs, and anticipated benefits are uncertain.
- After year-end, in February 2024, the FDA approved the EVOQUE system for tricuspid regurgitation. The filing also reports 2023 European approval. Other pipeline developments include trials and regulatory activity for TAVR and mitral therapies.
- The IRS issued a notice of deficiency seeking $269.3 million of additional tax, before interest and a repatriation-tax offset, concerning 2015–2017 Surgical/TAVR intercompany transfer pricing. Edwards plans to contest it and had not accrued an additional amount for the notice. The company intended to deposit a further $200–$300 million with the IRS by the second quarter of 2024 to limit interest while disputing the claim. Related years 2018–2023 remain under examination.
- Gross uncertain tax positions were $583.9 million; management estimated offsetting tax benefits of $250.7 million. The filing warns that outcomes of tax audits and disputes could materially affect results or financial condition.
- Other unresolved matters include a U.S. patent-infringement lawsuit concerning SAPIEN 3 Ultra, a European Commission investigation of certain business and patent practices, and a company-initiated FCPA review concerning activities in Japan and other markets. Their outcomes and potential financial impacts were not clear in the filing.
- Management cited competition, reimbursement and pricing pressure, clinical-trial and product-approval uncertainty, manufacturing and supplier risks, foreign exchange, hospital staffing and budget constraints, cybersecurity, and regulatory compliance as material risks. It reported no cybersecurity incident that had materially affected the company.
Most important facts for investors to verify
- Whether growth and margins in TAVR and TMTT continue, particularly given TAVR’s large share of sales and TMTT’s rapid growth from a smaller base.
- The cash-flow and earnings impact of Medtronic royalties and other costs associated with the intellectual-property agreement.
- Developments in the IRS transfer-pricing dispute, planned tax deposits, and the broader uncertain-tax-position balance.
- Progress, costs, tax treatment, and timing of the Critical Care spin-off.
- Inventory growth, foreign-exchange effects on margins, and the company’s ability to convert sales growth into operating cash flow.
- Regulatory, clinical, and commercial progress for EVOQUE, SAPIEN M3, and other pipeline programs, alongside the cited legal and regulatory investigations.